Cost-Effectiveness of CT Screening in the National Lung Screening Trial

Pinsky, Paul F.

doi:10.1056/nejmc1414726

Cited by 12 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this is likely to change as low-dose CT screening programs in populations at risk have shown benefits and are being widely implemented (Aberle et al, 2011; Black et al, 2015). Five-year survival rates for patients with pathologic stage IA and IB NSCLC are only 83% and 71%, respectively, and these numbers drop to 50% for stage II disease (Goldstraw et al, 2016) with minimal improvement from adjuvant chemotherapy (Pignon et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Lavin

Kobayashi

Leader

et al. 2017

Cell

990

883

View full text Add to dashboard Cite

Summary To guide the design of immunotherapy strategies for patients with early stage lung tumors, we developed a multiscale immune profiling strategy to map the immune landscape of early lung adenocarcinoma lesions to search for tumor-driven immune changes. Utilizing a barcoding method that allows a simultaneous single cell analysis of the tumor, non-involved lung and blood cells together with multiplex tissue imaging to assess spatial cell distribution, we provide a detailed immune cell atlas of early lung tumors. We show that stage I lung adenocarcinoma lesions already harbor significantly altered T cell and NK cell compartments. Moreover, we identified changes in tumor infiltrating myeloid cell (TIM) subsets that likely compromise anti-tumor T cell immunity. Paired single cell analyses thus offer valuable knowledge of tumor-driven immune changes, providing a powerful tool for the rational design of immune therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Lavin

Kobayashi

Leader

et al. 2017

Cell

990

883

View full text Add to dashboard Cite

show abstract

“…The prevalence of early-stage cases has significantly increased owing to the increasing use of low-dose CT (LDCT) for lung cancer screening in high-risk groups (37). Optimizing treatment strategies and clinical management of early-stage diseases is therefore required to improve the prognosis of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma

Huang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe prevalence of patients newly diagnosed with early-stage lung adenocarcinoma (LUAD) is growing alongside significant advances in screening approaches. This study aimed to construct ferroptosis-related gene score (FRGscore) for predicting recurrence, explore immune-molecular characteristics, and determine the benefit of immunotherapy in distinct ferroptosis-based patterns and FRGscore-defined subgroups.MethodsA total of 1,085 early-stage LUAD patients from four independent cohorts were included. Consensus clustering analysis was performed using 217 co-expressed FRGs to explore different ferroptosis-mediated patterns. An FRG scoring system was established to predict relapse, quantify ferroptosis-mediated patterns, and evaluate the response to immunotherapy in individual patients based on Lasso-penalized and stepwise Cox regression analyses. Immune landscape involving multiple parameters was further evaluated, stratified by cluster subtypes and FRGscore subgroups.ResultsTwo ferroptosis-mediated patterns were identified and verified, which were characterized by significantly distinct prognosis and immune profiles. Analyses of immune characteristics showed that identified ferroptosis patterns were characterized as immune-inflamed phenotype and immune-exhausted phenotype. The FRG scoring model based on 11 FRG-derived signatures panel classified patients into the FRGscore-high and FRGscore-low subgroups. Significantly longer recurrence-free survival (RFS) and overall survival (OS) were observed in the FRGscore-low subgroup. FRGscore-low patients were characterized by higher tumor mutational burden (TMB), immunoscore, immunophenoscore, and PD-L1 expression level and were associated with lower Tumor Immune Dysfunction and Exclusion (TIDE) score, whereas the opposite was observed in FRGscore-high patients. Immune-active pathways were remarkably enriched in the FRGscore-low subgroup. This scoring model remained highly predictive of prognosis across different clinical, molecular, and immune subgroups. Further analysis indicated that FRGscore-low patients exhibited higher response to anti-PD-1/PD-L1 immunotherapy and better clinical benefits based on two independent immunotherapy cohorts.ConclusionThe proposed FRGscore could highly distinguish the recurrence patterns and molecular and immune characteristics and could predict immunotherapy prognosis, potentially representing a powerful prognostic tool for further optimization of individuated treatment and management strategies in early-stage LUAD.

show abstract

“…One study, the National Lung Screening Trial, went beyond validation to associate the low-dose computed tomography to a 20% reduction in lung-cancer mortality. [ 25 ] This method is an example of not only innovative preventative care, but also one that is cost effective and worth continued research efforts. This must be done in our industry now.…”

Section: Proving Value With Utility Studiesmentioning

confidence: 99%

An industry perspective: An update on the adoption of whole slide imaging

Montalto¹

2016

Journal of Pathology Informatics

View full text Add to dashboard Cite

This manuscript is an adaptation of the closing keynote presentation of the Digital Pathology Association Pathology Visions Conference 2015 in Boston, MA, USA. In this presentation, analogies are drawn between the adoption of whole slide imaging (WSI) and other mainstream digital technologies, including digital music and books. In doing so, it is revealed that the adoption of seemingly similar digital technologies does not follow the same adoption profiles and that understanding the unique aspects of value for each customer segment is critical. Finally, a call to action is given to academia and industry to study the value that WSI brings to the global healthcare community.

show abstract

Cost-Effectiveness of CT Screening in the National Lung Screening Trial

Abstract: BACKGROUND-The National Lung Screening Trial (NLST) showed that screening with lowdose computed tomography (CT) as compared with chest radiography reduced lung-cancer mortality. We examined the cost-effectiveness of screening with low-dose CT in the NLST.

Cited by 12 publications

References 25 publications

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma

An industry perspective: An update on the adoption of whole slide imaging

Contact Info

Product

Resources

About